T. I. Kushnir

T. I. Kushnir

Auto-generated profile, based on publicly available information

T. I. Kushnir

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
TKT. I. Kushnir
T. I. Kushnir
NAN. E. Arnotskaya
N. E. Arnotskaya
IKI. A. Kudryavtsev
I. A. Kudryavtsev
AMA. A. Mitrofanov
A. A. Mitrofanov
ABAli Bekyashev Bekyashev
Ali Bekyashev Bekyashev
VSV. E. Shevchenko
V. E. Shevchenko
Background. Glioblastoma multiforme (GBM) develops in the hypoxic microenvironment, which plays an important role in the pathogenesis of the disease and is closely associated with tumor growth, development and poor prognosis. Hypoxia increases the resistance of tumor cells (TC) to radiation therapy and chemotherapy, promotes the appearance of an aggressive TC phenotype, leading to the disease recurrence. The molecular mechanism of hypoxic action on the secretome of GBM cells, which is involved in the formation of the tumor microenvironment, remains unclear. Also, markers of the aggressive hypoxia-associated phenotype of tumor cells have not been established. The purpose of research – to study the molecular mechanisms of the hypoxia-associated effect on the secretome of the U251 GBM cells.Materials and method. High resolution proteomic mass spectrometry, cell technologies.Results. A total of 1432 proteins were identified in the secretomes of two types of GBM cells (control and experiment). After the action of hypoxia, statistically significant changes in the expression of 390 proteins were registered. 11 proteins showed increase in expression over two orders of magnitude. The intracellular signaling pathways which are responsible for the hypoxia-associated effects on the U251 GMB cells have been identified.Conclusions. Hypoxia significantly affected the proteomic composition of the GBM cells secretome. Five overexpressed secretome proteins, S100A6, HEY1, ZIP3, S100A4, ZEB2, have been proposed as potential markers of the hypoxiaassociated phenotype of GBM, for which participation in the pathogenesis of glioblastoma multiforme has been previously showed.

15 May 2023 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
NAN. E. Arnotskaya
N. E. Arnotskaya
TKT. I. Kushnir
T. I. Kushnir
IKI. A. Kudryavtsev
I. A. Kudryavtsev
AMA. A. Mitrofanov
A. A. Mitrofanov
ABAli Bekyashev Bekyashev
Ali Bekyashev Bekyashev
VSV. E. Shevchenko
V. E. Shevchenko
Introduction. Glioblastoma (GB) is not yet curable despite recent advances in the treatment of other malignant solid tumors. The management of GB is based solely on histopathological features, imaging of the tumor and its genomic analysis (somatic mutations in the isocitrate dehydrogenase genes, methylation status of the O6-methylguanine-DNA methyltransferase gene promoter). To adapt the treatment to the most recent tumor evolution, molecular information should be received regularly throughout the course of therapy. However, tumor tissue is often not available for diagnosis as the disease progresses. In this regard, the development of less invasive methods, such as analysis of the proteome of biological fluids of patients, is of particular interest. Cerebrospinal fluid (CSF) is an important source disease biomarkers to monitor the presence and progression of the disease.Aim. To identify proteomic predictive biomarkers in the CSF of patients with GB.Materials and methods. During the study, samples of patients’ CSF samples, high-resolution proteomic mass spectrometry, modern biochemical methods and bioinformatic technologies were used.Results. For the first time, the analysis of proteomes of CSF samples of patients with GB obtained before and 7 days after the removal of the primary tumor was carried out. Potential biomarkers of GB have been identified. After their validation using open databases, 11 proteomic predictive markers of GB (S100A9, S100A8, PLA2G15, PPIB, LTBP2, VIM, LAMB1, STC1, NRP1, COL6A1, HSPA5) were selected and their role in the molecular mechanisms of gliomagenesis was assessed. Conclusion. The proposed panel of proteomic predictive CSF biomarkers in GB patients can be further used in the development of test systems for assessing the effectiveness of therapy and early detection of disease relapses.

15 January 2020 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
TKT. I. Kushnir
T. I. Kushnir
NAN. E. Arnotskaya
N. E. Arnotskaya
IKI. A. Kudryavtsev
I. A. Kudryavtsev
VSV. E. Shevchenko
V. E. Shevchenko
Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly type of primary malignant brain tumor, with a patien’s median survival rate ranging from 12 to 15 months. Over the last fifteen years, the treatment for GBM has included maximal safe surgical resection with combination radiotherapy and adjuvant temozolomide chemotherapy. The low efficacy of mentioned therapies has forced researchers to explore an appropriate alternative or complementary treatment for GBM. It has been shown that curcumin has therapeutic potentials to fight against GBM via affecting on cell proliferation, apoptosis, cell cycle, invasion and angiogenesis pathways. In addition, curcumin possess a synergistic impact with chemotherapeutic agents. Herein, we summarized the current findings on curcumin as potential therapeutic agent in the treatment of GBM.

6 October 2025 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VSV. E. Shevchenko
V. E. Shevchenko
TKT. I. Kushnir
T. I. Kushnir
MGM. V. Gudkova
M. V. Gudkova
NAN. E. Arnotskaya
N. E. Arnotskaya
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with aging and is a risk factor of many diseases including malignant neoplasms (MNPs). It originates through somatic mutations in hematopoietic stem and/or progenitor cells, promotes development of hematological MNPs and underlies unfavorable prognosis in solid malignant tumors. Results of recent largescale genome-wide studies confirmed that CHIP plays a role in oncological diseases. Mutations associated with this pathology were found in stem and/or progenitor cells in patients with both hematological and solitary MNPs which indicates that CHIP potentially mediates development of malignant tumors. Cytotoxic chemoradiation therapy is closely associated with CHIP development and causes emergence of aggressive and treatment-resistant hematological MNPs. In patients with solitary MNPs, TET2 gene mutations with high variant allele frequencies were also found in the tumors. This phenomenon was named tumor-infiltrating clonal hemopoiesis. Further populational studies of patients with solitary MNPs will allow to evaluate the role of tumor-infiltrating clonal hemopoiesis in oncogenesis. The ability of age-associated somatic clonal expansions in one tissue, namely hematopoietic compartment, to affect oncogenesis in another tissue is a new concept requiring further investigation and potentially capable of providing deeper understanding of cancer biology.The review explores the association between CHIP, aging, and oncological diseases with a particular emphasis on solitary MNPs. The ways for better understanding of the role of CHIP in oncogenesis and possibilities of using its clinical potential for cancer treatment are discussed.

15 January 2018 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VSV. E. Shevchenko
V. E. Shevchenko
ABA. S. Bryukhovetskiy
A. S. Bryukhovetskiy
MFMichael Filatov
Michael Filatov
VBV. S. Burdakov
V. S. Burdakov
ZNZ. N. Nikiforova
Z. N. Nikiforova
ЮВЮ. Д. Василец
Ю. Д. Василец
Background. Multiple myeloma (MM) is a hematologic malignancy of plasma cells. The microenvironment plays a key role in MM cell survival and drug resistance through release of soluble factors, expression of adhesion molecules and release of exosomes (EXs). The role that EXs, released by MM cells have in cell-to-cell communication and signaling in the bone marrow is currently unknown. EXs as a source of markers for MM diagnostics are also not studied.Objective: to use proteomic profiling of EXs as a tool to identify circulating tumor associated markers in MM patients.Results. The proteome composition of EXs obtained from plasma of patients with MM and multiple sclerosis was studied for the first time. nano-HPLC–MS/MS analysis identified a total of 332 proteins in the EXs of both groups of patients and determined the proximity of their qualitative composition. For the first time, 12 differentially expressed proteins were detected, the levels of which were significantly increased in EXs from patients with MM. This allowed us to consider them as potential markers of the disease.Conclusion. Proteomic analysis of EXs obtained from plasma of patients with MM is an important method for finding disease markers.

15 September 2022 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VSV. E. Shevchenko
V. E. Shevchenko
ZNZ. N. Nikiforova
Z. N. Nikiforova
TKT. I. Kushnir
T. I. Kushnir
IKI. A. Kudryavtsev
I. A. Kudryavtsev
AMA. A. Mitrofanov
A. A. Mitrofanov
NAN. E. Arnotskaya
N. E. Arnotskaya
Introduction. Treatment of glioblastoma multiforme remains little effective due to the rapidly developing recurrence of the tumor, due to its high tumorigenic potential, resistance to chemoradiation therapy and increased dissemination of glioma stem cells. The identification of potential therapeutic targets, which make it possible to more effectively destroy glioma stem cells, becomes topical. In this regard, the study of ferroptosis (FP), which can cause the death of tumor cells with a highly malignant phenotype, is of great importance. However, FP and its regulatory pathways in the GSC are not fully understood. At present, it is also not clear how FP differs for glioma stem cells and glioblastoma differentiated cells.Aim. To study the expression of ferroptosis signaling cascade determinants in CD133+ glioma stem cells and CD133- glioblastoma differentiated cells using high resolution proteomic mass spectrometry.Materials and methods. High-resolution proteomic mass spectrometry, cell technologies.Results. In total, 1970 proteins were identified, 15 of which are associated with ferroptosis and are present in both cell populations. Upregulation of 12 FP determinants (ACSL1, ACSL3, COPZ1, FTH1, FTL, GPX1, GPX4, PCBP1, SLC3A2, TFRC, VDAC1, VDAC2) was found in CD133+ glioblastoma stem cells compared to CD133- differential glioblastoma cells, 10 of which were more than 2-fold overexpressed.Conclusion. Important regularities have been established in the expression of ferroptosis determinants and proteins controlling this process in glioma stem cells, which can be used in the development of new approaches to the detection of potential targets for the therapy of glioblastoma multiforme.